Tempero Spotlights Frontline Treatment Options in Pancreatic Cancer

Newsfeed Image, Light Gray Text On Dark Gray Background
The results of a clinical trial exploring pegvorhyaluronidase alfa (PEGPH20) in combination with nab-paclitaxel (Abraxane) and gemcitabine could impact practice for physicians who treat patients with pancreatic cancer, says Margaret A. Tempero, MD.

Early clinical trials have revealed that PEGPH20 shows a benefit in patients with metastatic hyaluronan (HA)-high pancreatic cancer. The agent is being investigated in combination with gemcitabine and nab-paclitaxel in the same setting in the phase III HALO-109-301 trial. Read more . . .


Conversation